Prevalence of FODMAP Intolerance and JHS in FGID and Association With Microbiome, Dyssynergic Defecation and Dietary Intervention (PreDiMi)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03460613|
Recruitment Status : Unknown
Verified March 2018 by University of Zurich.
Recruitment status was: Recruiting
First Posted : March 9, 2018
Last Update Posted : March 9, 2018
Irritable bowel syndrome (IBS) is a disorder of gastrointestinal function characterized by abdominal symptoms and pain associated with alterations in bowel habit. The condition impacts on the quality of life of at least 10% of the population, impacts on activities of daily living and is associated with considerable direct and indirect costs to the individual, the health system and society. The etiology of IBS appears multifactorial and several mechanisms, among them mucosal inflammation, abnormal intestinal motility, visceral hypersensitivity and psychological factors, appear to be involved.
An underlying pathophysiology, namely Joint Hypermobility (JH) and Joint Hypermobility Syndrome (JHS), that we are going to study, have recently gained increasing attention in patients with functional bowel disease.
One factor which was shown in previous IBS-studies to reduce abdominal symptoms is a FODMAP diet.
To identify FGID patients which profit most from different diagnostics and therapies (such as FODMAP diet) we are going to carry out a study analyzing different subtypes of FGID (in particular IBS, FD, functional abdominal pain/bloating) for demographics, clinical diagnostics (e.g. nutrient challenge testing, microbiome testing, anorectal manometry and MR defecography), comorbidities (in particular JH, JHS and psychological comorbidities) and treatment.
|Condition or disease||Intervention/treatment||Phase|
|Functional Gastrointestinal Disorders||Other: FODMAP diet||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||650 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prevalence of FODMAP Intolerance and Joint Hypermobility Syndrome in Functional Bowel Patients and Association With Microbiome, Dyssynergic Defecation and Dietary Intervention - a Prospective Cohort Study With Health-related Intervention|
|Actual Study Start Date :||July 7, 2017|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||June 2020|
Other: FODMAP diet
Patients with a diagnosed FODMAP intolerance (and a control with no FODMAP intolerance) by prior nutrient challenge testing are going on a FODMAP diet. In a first nutritional visit a specialized nutritionist will inform the patients about FODMAP containing foods and illustrate a FODMAP elimination diet. After 3 weeks of elimination diet another visit will take place and a stepwise reintroduction diet is initiated after successful elimination diet.
|No Intervention: Hepatology Control Group|
|No Intervention: Healthy Volunteers|
- Prevalence of Joint Hypermobility / hypermobile Ehlers-Danlos Syndrome according to the criteria of the "2017 International Classification of the Ehlers-Danlos Syndromes" (hEDS) [ Time Frame: 15 minutes ]Prevalence of joint hypermobility resp. hEDS will be assessed by physicians according to the criteria of the "2017 International Classification of the Ehlers-Danlos Syndromes" in patients with disorders of gut-brain interactions (FGID). The assessment consists of some hypermobility testings (wrists, fingers, elbows, knees and legs) and questions about family hypermobility syndrome history, scars healing, hernia history etc.
- Prevalence of FODMAP intolerance according to nutrient challenge testing (NCT). [ Time Frame: 3-4 hours ]Prevalence of FODMAP intolerance in FGID patients will be assessed according to nutrient challenge testing (NCT). Patients drink a specific beverage containing a specific sugar. The hydrogen value in breath is then measured every 10 minutes and symptoms are recorded at the same time. Depending on the time of hydrogen production and the increase of abdominal symptoms can a FODMAP intolerance be determined.
- Response to dietary intervention [ Time Frame: 10-12 weeks ]FGID patients will be randomized according to the participants JH-status and according to the result of NCT to the dietary intervention. They will follow a specific intervention diet with guidance of a dietician and the abdominal symptoms will be assessed every 4 weeks approximately.
- Microbiome in FGID patients [ Time Frame: 3-4 weeks ]Microbiome changes after dietary intervention will be analyzed.
- Prevalence of outlet obstruction in IBS-C subgroup [ Time Frame: 1-3 hours ]Prevalence of outlet obstruction in a subgroup of FGID patients (IBS-C) will be analyzed by high resolution anorectal manometry and/or MR defecography
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03460613
|Contact: Daniel Pohl, PD Dr. email@example.com|
|Zürich, Switzerland, 8091|
|Contact: Daniel Pohl|
|Principal Investigator:||Daniel Pohl, PD Dr. med.||University of Zurich|